GlassScriptPhysician profile
Karley Sexton
NPI 1114520491
$1,455.41
in general payments reported to CMS, 2019-2025
20 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $200 · 2023: $337 · 2024: $398 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.34 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $268.10 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.77 | 2021-2024 | Xifaxan |
| Abbvie INC. | $104.64 | 2022-2025 | |
| Axsome Therapeutics, INC. | $102.10 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $86.21 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $74.06 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $73.57 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $52.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.13 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.39 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $24.18 | 2025 | Gemtesa |
| Medtronic, INC. | $21.78 | 2025 | Inceptiv |
| Exeltis, USA INC. | $20.64 | 2023 | Slynd |
| Verona Pharma, INC. | $20.56 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $17.53 | 2024 | Nexletol |
| Amgen INC. | $14.21 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2025 | Jardiance |
| Lilly USA, LLC | $12.60 | 2022 | |
| Pfizer INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karley Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.